ReviewBlood2009
The ITP syndrome: pathogenic and clinical diversity.
Review in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04113915 (Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy), which is not on this map. Cited by 290 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy
Who cites it
290 citing papers in PubMed, 6 syntheses or guidelines pooled it, 798 citations in OpenAlex.
- Evaluation ofFrontiers in medicine · 2026Pooled it
- Efficacy and safety of cyclosporine-based regimens for primary immune thrombocytopenia: a systematic review and meta-analysis.The Journal of international medical research · 2023Pooled it
- ANA-positive primary immune thrombocytopaenia: a different clinical entity with increased risk of connective tissue diseases.Lupus science & medicine · 2021Pooled it
- Efficacy and safety of rituximab for minors with immune thrombocytopenia: a systematic review and meta-analysis.The Journal of international medical research · 2020Pooled it
- American Society of Hematology 2019 guidelines for immune thrombocytopenia.Blood advances · 2019Guideline
- Efficacy and Safety of the Combination Treatment of Rituximab and Dexamethasone for Adults with Primary Immune Thrombocytopenia (ITP): A Meta-Analysis.BioMed research international · 2018Pooled it
- Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.Blood advances · 2020Trial
- Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series.British journal of haematology · 2020Trial
- Anti-platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications.Journal of thrombosis and haemostasis : JTH · 2020Trial
- IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP.Blood advances · 2020Trial
- Efficacy and safety of a new intravenous immunoglobulin (PanzygaTransfusion medicine (Oxford, England) · 2019Trial
- Platelet desialylation is a novel mechanism and a therapeutic target in thrombocytopenia during sepsis: an open-label, multicenter, randomized controlled trial.Journal of hematology & oncology · 2017Trial
- Persistent Immune Thrombocytopenia as a Post-Acute Sequelae of COVID-19: A Case Report.Public health challenges · 2026Article
- Article
- Association of carotid intima media thickness with cardiovascular disease risk in immune thrombocytopenia.International journal of hematology · 2026Article
- Successful eltrombopag discontinuation in paraneoplastic immune thrombocytopenia: a case report.Blood vessels, thrombosis & hemostasis · 2026Article
- Neutrophil-derived S100A8/A9 impairs megakaryocyte maturation in immune thrombocytopenia.Nature communications · 2026Article
- PSMA-Targeting Macrophage Membrane-Coated Nanoparticles for Precision Diagnosis and Combination Therapy of Prostate Cancer.Exploration (Beijing, China) · 2026Article
- The PI3K-AKT pathway mediates the imbalance of bone marrow macrophage polarization in patients with immune thrombocytopenia.Journal of translational medicine · 2026Article
- A Comparative Analysis of the Efficacy, Safety and Mechanism of Action of Flebogamma DIF, Fostamatinib and Romiplostim in Immune Thrombocytopenia.Life (Basel, Switzerland) · 2026Review
230 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Immune thrombocytopenia (ITP) is mediated by platelet autoantibodies that accelerate platelet destruction and inhibit their production. Most cases are considered idiopathic, whereas others are secondary to coexisting conditions. Insights from secondary forms suggest that the proclivity to develop platelet-reactive antibodies arises through diverse mechanisms. Variability in natural history and response to therapy suggests that primary ITP is also heterogeneous. Certain cases may be secondary to persistent, sometimes inapparent, infections, accompanied by coexisting antibodies that influence outcome. Alternatively, underlying immune deficiencies may emerge. In addition, environmental and genetic factors may impact platelet turnover, propensity to bleed, and response to ITP-directed therapy. We review the pathophysiology of several common secondary forms of ITP. We suggest that primary ITP is also best thought of as an autoimmune syndrome. Better understanding of pathogenesis and tolerance checkpoint defects leading to autoantibody formation may facilitate patient-specific approaches to diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.